The drug combo is the first dual checkpoint inhibitor therapy approved in Europe for first-line metastatic MSI-H or dMMR colorectal cancer.

NEW YORK – AstraZeneca on Monday said the European Commission approved its tyrosine kinase inhibitor Tagrisso (osimertinib) as a treatment for patients with advanced, unresectable non-small cell lung ...

Alyftrek is approved as a new treatment for cystic fibrosis, while the FDA expanded the label for Trikafta to include additional genetic mutations.

The firms are developing the autologous CAR T-cell therapy IB-T101 as a treatment for clear cell renal cell carcinoma.

R-targeted therapy PMB-CT01 for treating B-cell malignancies, including heavily pretreated follicular lymphoma.

The program, aimed at reducing how much Americans spend on prescription drugs, includes several precision medicines.

The company separately said it has started treating patients within a Phase III trial testing an ASO drug for Angelman syndrome.

NEW YORK – The US Food and Drug Administration on Friday granted accelerated approval to Pfizer's Braftovi (encorafenib) plus Eli Lilly's Erbitux (cetuximab) with chemotherapy for patients with newly ...

The agency's decision not to approve this formulation was based on issues identified during a pre-approval inspection at a manufacturing facility, the firm said.

AI-driven tools for prescreening patients, predicting responses and outcomes, and guiding patient therapy are maturing and entering the market.

The firm plans to launch trials to study the agent in biomarker-defined cancer types, including breast and lung cancers.

The company is using its Senza5 platform to produce CAR T cells without the CD5 receptor, hoping to enable smaller doses and avoid CAR-T fratricide.